PACIFIC EDGE ADVANCES US COMMERCIAL RECOVERY
19/10/2026 09:30 NZDT, GENERALP
PACIFIC EDGE ADVANCES US COMMERCIAL RECOVERY
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX/ASX: PEB) today reports increased momentum towards its US commercial recovery.
The company’s Q2 27 Investor Update, released today, also provides updates on:
- Proposed Medicare price increases of approximately 35% for Cxbladder Monitor and 39% for Cxbladder Triage, lifting the 2027 prices from the current US$760 to US$1,026 and US$1,058 respectively, subject to CMS finalization on 1 January 2027
- Cxbladder gained in-network coverage at Blue Cross plans in North and South Carolina from 1 November 2026. Pacific Edge has established policy and in-network contracting with these plans, which cover nearly 8 million lives
- Triage Plus received funding allocation within the Veteran’s Administration, Pacific Edge’s first facility-level Blanket Purchase Agreement within the US Veterans Administration system
- US commercial volumes declined 13.0% to 2,867 tests as Pacific Edge maintained lower commercial spending and repositioned towards reimbursable intermediate risk microhematuria patients, partly offset by a 3.7% increase in APAC commercial volumes
to 1,201 tests
- Triage Plus continued to gain traction, representing 5.6% of US tests in Q2 27 and 10.8% of tests in September 2026, up from 0.8% in Q1 27. Enrolment target of ~2000 patients achieved for the Triage Plus concordance study at KP SoCal
- Two new peer-reviewed clinical studies published strengthening the evidence base, with the Canterbury New Zealand study demonstrating faster access to specialist assessment and treatment, fewer avoidable referrals and improved equity for Māori, and the AUSSIE study validating Triage Plus in an Australian population
Pacific Edge Chief Executive Dr Peter Meintjes said: “The proposed pricing increases for Triage and Monitor, in-network contracting with Blue Cross plans and continued progress with
Triage Plus are encouraging signs that the building blocks for US commercial recovery are falling into place. Final Medicare coverage remains the critical near-term milestone. We continue to expect the policy to be finalized by the end of this calendar year. In the meantime, US volumes continue to reflect our disciplined approach to spending and the transition towards
reimbursable patients.”
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer
For more information:
Investors:
Dr Peter Meintjes
Chief Executive
P: +64 22 032 1263
Media:
Richard Inder
The Project
P: +64 21 645 643
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association’s Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.